Abstract:In allogeneic hematopoietic stem cell transplantation recipients, cytomegalovirus (CMV) infection can cause overt CMV-associated disease, which is a main cause of transplantation-associated mortality. CMV infection correlates closely with donor's type. We therefore examined whether risk factors of CMV reactivation and clinical endpoints in patients with hematologic malignancies after allogeneic peripheral blood stem cell transplantation (PBSCT) differed between using matched-sibling donors (MSD-SCT) and haploidentical donors (HID-SCT). In this retrospective cohort study, we enrolled in 200 consecutive patients received an unmanipulated G-CSF-mobilized allogeneic PBSCT. Ninety (45%) patients received MSD-SCT and 110 (55%) received HID-SCT. Quantitative PCR was used for monitoring of CMV reactivation after transplantation. One-year cumulative incidence of CMV DNAemia was 55.0%, ranging from 23.5% in MSD-SCT group to 81.0% in HID-SCT group (p < 0.001). Although univariate analyses showed that non-myeloid malignancies, disease in complete remission status at transplantation, pretreatment with antithymocyte globulin, HLA-haploidentical donors, male donors, previous Epstein-Barr virus DNAemia, and absolute lymphocyte count on day 30 < 0.6 × 109/L were respectively associated with CMV reactivation after transplantation in total cohort of recipients (all p < 0.05), haploidentical donors were found to be the only independent predictor in multivariate analyses (Hazard ratio = 6.4, p < 0.001). Furthermore, univariate analyses revealed that non-myeloid malignancies and previous Epstein-Barr virus DNAemia were respectively associated with CMV reactivation in MSD-SCT recipients, and female was associated with CMV reactivation in HID-SCT recipients (all p < 0.05). In HID-SCT recipients, but not MSD-SCT recipients, previous CMV DNAemia was associated with a lower cumulative incidence of acute graft-versus-host disease (49.2% vs. 72.6%, p < 0.001). CMV DNAemia did not play a role in the relapse rate, but it was strongly associated with an increased risk of non-relapse mortality either in total cohort of recipients (30.5% vs. 13.7%; p = 0.003) or in the HID-SCT subgroup (36.0% vs. 16.7%; p = 0.030). Relapse-free survival and overall survival in total cohort of recipients with CMV DNAemia were both inferior to those without CMV DNAemia (45.3% vs. 57.6% and 54.8% vs. 65.8%, respectively; both p < 0.05). However, in subgroup analysis according to donor's type, neither relapse-free survival nor overall survival was impacted by CMV status (both p > 0.05). This study addressed differences in incidence, risk factors, and associations with clinical outcomes of CMV reactivation after haploidentical versus matched-sibling PBSCT.

Risk factors and clinical outcomes of cytomegalovirus diseases in hematologic malignancy patients without hematopoietic stem-cell transplantation: a case-control study

Risk Factors and Clinical Outcomes of Cytomegalovirus Diseases in Hematologic Malignancy Patients Without Hematopoietic Stem-Cell Transplantation.

Risk Factors for Cytomegalovirus Gastrointestinal Diseases in Adult Patients with Cancer

Risk Factors and Associations with Clinical Outcomes of Cytomegalovirus Reactivation after Haploidentical Versus Matched-Sibling Unmanipulated PBSCT in Patients with Hematologic Malignancies.

Clinical Presentation and Risk Factors for Cytomegalovirus Colitis in Immunocompetent Adult Patients

Cytomegalovirus infection in patients with malignant lymphomas who have not received hematopoietic stem cell transplantation

Cytomegalovirus infection in intensive care unit patients with hematological malignancies: Characteristics and clinical outcomes

Early Immune Surveillance to Predict Cytomegalovirus Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation.

[Cytomegalovirus Diseases after Allogeneic Hematopoietic Stem Cell Transplantation (Allo-Hsct) and Related Risk Factors].

Clinical and healthcare burden of disease associated with cytomegalovirus in allogeneic hematopoietic stem cell transplantation - A retrospective single-center study

Cytomegalovirus in Allogeneic Hematopoietic Transplantation: Impact on Costs and Clinical Outcomes Using a Preemptive Strategy

Patients with Refractory Cytomegalovirus (CMV) Infection Following Allogeneic Haematopoietic Stem Cell Transplantation Are at High Risk for CMV Disease and Non-Relapse Mortality.

Predictors of cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: Insights from a real-world experience

Risk factors for cytomegalovirus DNAemia following haploidentical stem cell transplantation and its association with host hepatitis B virus serostatus.

Quantitative Monitoring of Blood Cytomegalovirus after Allogeneic Hematopoietic Stem Cell Transplantation and Its Clinical Significance

Cytomegalovirus infection and rehospitalization rates after allogeneic hematopoietic stem cell and solid organ transplantation: a retrospective cohort study using German claims data

CD34+ cell dose and CMV viremia after haploidentical hematopoietic stem cell transplantation: a retrospective study

Incidence, Risk Factors, and Outcomes of Cytomegalovirus Retinitis after Haploidentical Hematopoietic Stem Cell Transplantation

[Risk Factors of Cytomegalovirus Infection and Antiviral Efficacy in Recipients of Hematopoietic Stem Cell Transplantation].

Impact and outcomes of primary cytomegalovirus disease in seronegative abdominal solid organ transplant recipients of cytomegalovirus unexposed donors (D‐/R‐)

[Clinical Study of 34 Patients with Cytomegalovirus Pneumonia after Allogeneic Hematopoietic Stem Cell Transplantation].